10 recruiting, 8 completed, 5 active not recruiting, 3 terminated. 15 Phase 1, 12 Phase 2, 7 Phase 3, 1 Not applicable.
Follow Allist Pharmaceuticals, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST） Firmonertinib, Placebo - NSCLC, Adjuvant Treatment | Phase 3 | Recruiting | Allist Pharmaceuticals, Inc. | 338 | 2025-05-28 | 2026-08-13 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Tablets) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer AST2303 Tablets(ABK3376 Tablets) ，25mg, AST2303 Tablets(ABK3376 Tablets) ，50mg, AST2303 Tablets(ABK3376 Tablets) ，75mg - Locally Advanced or Metastatic Non-small Cell Lung Cancer | Phase 1 | Recruiting | Allist Pharmaceuticals, Inc. | 120 | 2025-03-04 | 2026-08-13 |
| Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation Firmonertinib Mesilate Tablets, Pemetrexed Disodium for Injection, Cisplatin for injection - EGFR, NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 3 | Recruiting | Allist Pharmaceuticals, Inc. | 300 | 2024-11-19 | 2026-08-13 |
| A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases Furmonertinib Mesilate Tablets, Carboplatin Injection, Cisplatin for injection - NSCLC Patients With Brain Metastasis | Phase 3 | Recruiting | Allist Pharmaceuticals, Inc. | 380 | 2024-09-26 | 2026-08-13 |
| JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation JAB-21822, Tislelizumab, JAB-3312 - Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer | Phase 3 | Recruiting | Allist Pharmaceuticals, Inc. | 392 | 2024-08-07 | 2026-08-13 |
| A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects JAB-21822, Itraconazole, Omeprazole - Healthy Subjects | Phase 1 | Completed | Allist Pharmaceuticals, Inc. | 66 | 2023-11-25 | 2025-04-04 |
| A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation. JAB-21822 - KRAS P.G12C, Pancreatic Cancer | Phase 2 | Recruiting | Allist Pharmaceuticals, Inc. | 88 | 2023-10-27 | 2026-03-13 |
| Mass Balance Study of [14C]JAB-21822 [14C]JAB-21822 - Mass Balance Study in Healthy Subjects | Phase 1 | Completed | Allist Pharmaceuticals, Inc. | 6 | 2023-07-08 | 2025-04-04 |
| Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) furmonertinib 240 mg oral, daily, furmonertinib 160 mg oral, daily, platinum-based chemotherapy - Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer | Phase 3 | Active not recruiting | ArriVent BioPharma, Inc. | 398 | 2023-06-01 | 2025-06-22 |
| A Food Effect Study of JAB-21822 in Healthy Subjects JAB-21822 - Food Effect in Healthy Participants | Phase 1 | Completed | Allist Pharmaceuticals, Inc. | 18 | 2023-05-12 | 2025-04-04 |
| Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion Furmonertinib - NSCLC | Phase 2 | Active not recruiting | Allist Pharmaceuticals, Inc. | 100 | 2022-09-27 | 2026-08-14 |
| A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1 JAB 21822 - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Allist Pharmaceuticals, Inc. | 104 | 2022-08-17 | 2026-08-13 |
| Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA Furmonertinib, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab - Non-small Cell Lung Cancer | Phase 2 | Recruiting | Sun Yat-sen University | 280 | 2022-05-06 | 2022-08-31 |
| Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation JAB-21822, JAB-3312 - KRAS P.G12C, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Allist Pharmaceuticals, Inc. | 240 | 2022-04-14 | 2026-08-13 |
| JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation JAB-21822, Cetuximab - Advanced Colorectal Cancer, Small Intestinal Cancer | Phase 1 / Phase 2 | Active not recruiting | Allist Pharmaceuticals, Inc. | 48 | 2022-02-17 | 2026-03-16 |
| Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE) Furmonertinib (160mg) - Non-Small-Cell Lung Cancer | Phase 2 | Unknown | Fudan University | 62 | 2021-12-09 | 2022-08-04 |
| Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC Furmonertinib, Anlotinib - Non-Small-Cell Lung Cancer | Phase 2 | Unknown | Shanghai Chest Hospital | 40 | 2021-10-12 | 2023-01-06 |
| Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation Furmonertinib 240mg, Furmonertinib 160mg - NSCLC | Phase 1 | Withdrawn | Allist Pharmaceuticals, Inc. | 2021-10-01 | 2025-03-14 | |
| Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT) Furmonertinib - Lung Adenocarcinoma | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 40 | 2021-08-01 | 2021-07-16 |
| A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China JAB-21822 - NSCLC, Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | Allist Pharmaceuticals, Inc. | 315 | 2021-07-26 | 2026-08-13 |
Showing 20 of 30. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (11) · Carcinoma, Pancreatic Ductal (2) · Colorectal Neoplasms (2) · Adenocarcinoma of Lung (1) · Appendiceal Neoplasms (1) · Breast Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Noonan Syndrome (1) · Pancreatic Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
aflutinib (14) · Carboplatin (3) · Pemetrexed (3) · Cisplatin (2) · Injections (2) · osimertinib (2) · Cetuximab (1) · Digoxin (1) · Gefitinib (1) · Itraconazole (1) · Midazolam (1) · Omeprazole (1) · Platinum Compounds (1) · Rifampin (1) · Rosuvastatin Calcium (1)
China (27) · United States (2) · Australia (1) · Brazil (1) · Canada (1) · France (1) · Israel (1) · Italy (1) · Japan (1) · Malaysia (1) · Mexico (1) · Netherlands (1) · Philippines (1) · Singapore (1) · South Korea (1)
He Qing B.Pharm (2) · Baohui C Han, PHd (1) · Changli Wang, MD (1) · Fan Yang, Doctor (1) · Hui Yu, MD (1) · Jianxing He, PHD (1) · Li Zhang, Master (1) · LiYan Miu (1) · Morgan Lam (1) · Shi YK (1) · Wang Jie M.D. (1) · Wang Wang Jie M.D. (1)
PMID 32007598, PMID 40333694, PMID 41344351, PMID 42384131, PMID 33780662, PMID 35662408, PMID 39762419, PMID 41037823, PMID 41325755